Publication:
Brentuximab vedotin for relapsed or refractory hodgkin lymphoma: Experience in Turkey

dc.contributor.authorFerhanoglu, B.
dc.contributor.authorSalihoğlu, A.
dc.contributor.authorElverdi, T.
dc.contributor.authorKaradoğan, I.
dc.contributor.authorÖzdemir, E.
dc.contributor.authorErdem, G.
dc.contributor.authorKaradurmus, N.
dc.contributor.authorAkyol, G.
dc.contributor.authorKaynar, L.
dc.contributor.authorYeğin, A.
dc.contributor.authorSucak, G.
dc.contributor.authorÖzcan, M.
dc.contributor.authorBirtaş, E.
dc.contributor.authorGöker, H.
dc.contributor.authorBaslar, Z.
dc.contributor.authorPaydaş, S.
dc.contributor.authorTopçuoğlu, P.
dc.contributor.buuauthorÖzkocaman, V.
dc.contributor.buuauthorÖZKOCAMAN, VİLDAN
dc.contributor.departmentTıp Fakültesi
dc.contributor.researcheridAAH-1854-2021
dc.date.accessioned2024-08-15T08:07:57Z
dc.date.available2024-08-15T08:07:57Z
dc.date.issued2014-06-01
dc.descriptionBu çalışma, 12-15 Haziran 2014 tarihleri arasında Milan[İtalya]’da düzenlenen 19. Congress of the European-Hematology-Association’da bildiri olarak sunulmuştur.
dc.identifier.endpage676
dc.identifier.issn0390-6078
dc.identifier.issueSupplement 1
dc.identifier.startpage675
dc.identifier.urihttps://hdl.handle.net/11452/44044
dc.identifier.volume99
dc.identifier.wos000342830903240
dc.indexed.wosWOS.SCI
dc.indexed.wosWOS.ISTP
dc.language.isoen
dc.publisherFerrata Storti Foundation
dc.relation.journalHaematologica
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectHematology
dc.titleBrentuximab vedotin for relapsed or refractory hodgkin lymphoma: Experience in Turkey
dc.typeMeeting Abstract
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi
relation.isAuthorOfPublication516d4442-e436-45a6-87b9-741a9e213d31
relation.isAuthorOfPublication.latestForDiscovery516d4442-e436-45a6-87b9-741a9e213d31

Files